Can HIV Be Cured? Where Research Stands Today Headlines about an HIV cure appear regularly. Sometimes they focus on gene therapy, sometimes on antibodies or genetically modified immune cells. For people living with HIV, such reports can offer hope, but they can also be confusing. Is an HIV cure…
Can HIV Be Cured? Where Research Stands Today
Headlines about an HIV cure appear regularly. Sometimes they focus on gene therapy, sometimes on antibodies or genetically modified immune cells. For people living with HIV, such reports can offer hope, but they can also be confusing. Is a cure really within reach? Or are expectations being raised that research is not yet able to meet?
The short answer is: HIV cure research has made enormous progress in recent years. At the same time, there is currently no widely available treatment that can reliably and permanently cure HIV.
This article aims to help put the current state of research into realistic perspective and support people who are considering taking part in a cure study.
The success story of HIV treatment has changed the standard
Forty years ago, HIV infection was almost always life-threatening. Thirty years ago, in 1996, combination therapy represented a medical breakthrough. Today, modern antiretroviral therapy (ART) gives most people living with HIV a near-normal life expectancy. When treatment is successful, HIV is not sexually transmitted (“U = U”), and many people experience treatment as a routine part of everyday life.
But this also presents a particular challenge for cure research: A new therapy no longer has to be better than untreated HIV infection—it has to measure up against a treatment that is already highly effective and comparatively safe.
The good news: an HIV cure is biologically possible
For a long time, it was not even clear whether HIV could be cured at all. Today, we know that, in principle, it can.
Experts distinguish between two goals: a sterilizing cure, in which the virus is completely eliminated from the body (also called “eradication”), and a functional cure (also called “remission”), in which HIV remains in the body but is permanently controlled without medication. Most current approaches target the more realistic second goal.
Several people are now living for years without HIV medication after receiving stem-cell transplants for leukemia or another serious blood cancer.[1] In the first such cases, the donors carried a rare genetic change (the “CCR5-Δ32 mutation”) that prevents most HIV variants[2] from infecting immune cells carrying the mutation.
Siegfried Schwarze:
A new therapy [for an HIV cure] no longer has to be better than untreated HIV infection—it has to measure up against a treatment that is already highly effective and comparatively safe.
It has since become clear, however, that this mutation is not the sole explanation for HIV cure. The “second Berlin patient”[3] had a donor who carried the mutation in only one of their two gene copies; in the case of the “Geneva patient,” the mutation was absent altogether—and yet HIV disappeared. Several factors probably work together, including the new HIV-targeting immune system generated from the donor cells. The exact mechanisms are currently being investigated.
Previous HIV cures: scientific milestones, but not a realistic treatment option
These cases are regarded as scientific milestones. They demonstrate that, under certain circumstances, HIV can permanently disappear—or at least be suppressed so extensively that treatment is no longer necessary.
For the vast majority of people living with HIV, however, this procedure is not a realistic treatment option. A stem-cell transplant is among the most intensive treatments in modern medicine. It carries substantial risks—the procedure-related mortality risk can reach double-digit percentages depending on the patient’s initial condition, age, and procedure, and in older statistics was sometimes above 30%—and is performed only when necessary to treat a life-threatening cancer.
The fundamental task of cure research today is therefore: How can the same result be achieved using much safer procedures?
Why HIV is so difficult to defeat
The biggest challenge for cure research is not the “free” virus in the bloodstream, but the virus that hides inside cells and remains “silent.”
Immediately after HIV infection, individual viruses enter long-lived immune cells and integrate their genetic material into the cell’s DNA. These cells can then remain dormant for years or even decades. In this state, they produce little or no new virus and therefore remain virtually invisible to the immune system. HIV medications, meanwhile, can block viral replication but cannot eliminate these already infected, dormant cells.
Siegfried Schwarze:
The biggest challenge for HIV cure research is not the “free” virus in the bloodstream, but the virus that hides inside cells and remains “silent.”
These so-called viral reservoirs are the main reason HIV usually becomes detectable again within days to weeks after treatment is stopped. Once the protection provided by ART is removed, these cells can become active again and produce new virus.
The key question, therefore, is not: “How do we eliminate the virus in the blood?” but rather: “How do we reach the few infected cells hiding throughout the body?” Their number is small—estimates suggest that only about one in a million resting immune cells carries replication-competent HIV—but even that is enough for the infection to rebound. Researchers around the world are working on this problem.
Possible paths to an HIV cure: the main research approaches
New terms and abbreviations regularly appear in the media. Behind them, however, are several fundamental strategies.
Treatment intensification
Here, ART is strengthened by adding additional drugs to suppress even the smallest traces of viral replication. The idea is that if no new cells are infected, the reservoir can no longer replenish itself. Since infected cells gradually die naturally, the reservoir would slowly shrink over time—effectively being “starved.”
The problem is that the reservoirs are extremely long-lived. Estimates suggest that this approach would take several decades[4]. It might therefore be suitable, at most, for people treated very early who have a small viral reservoir.
CCR5 knockout
Instead of using donor cells, it may be possible to modify a person’s own stem cells with “gene scissors” such as CRISPR so that they no longer produce CCR5, a gateway used by the virus to enter cells. Early studies are underway.
However, this requires so-called conditioning: a form of preparatory chemotherapy that creates space in the bone marrow for the modified cells. It can involve significant side effects.
Cutting out or silencing HIV’s genetic material
After infection, HIV permanently integrates its genetic material into the cell’s DNA. This integrated blueprint is called a provirus. Customized gene-editing tools are intended either to cut it out or permanently silence it.
The risks vary depending on the method. With CRISPR/Cas, for example, unintended cuts can occur at the wrong locations in DNA (“off-target effects”), potentially resulting in faulty proteins or disruption of other genes.
For the alternative Brec1 recombinase, extensive laboratory studies indicate a favorable safety profile: no detectable cell- or DNA-damaging effects were found. However, these data come from the developing research group and preclinical experiments; its first use in humans has yet to take place.
In the first human study of the CRISPR drug EBT-101, there were no serious side effects, but it did not prevent viral rebound after ART was stopped. It remains unclear whether all infected cells can be reached—and whether that is even necessary.
“Shock & Kill”[5]
The idea is to deliberately activate dormant cells (“shock”) so that the sleeping virus awakens and becomes vulnerable to ART and the immune system (“kill”).
Many early approaches, however, were either too toxic or insufficiently effective; massive immune activation can resemble sepsis (blood poisoning). Newer strategies aim to activate cells more selectively while simultaneously strengthening the immune response.
“Block & Lock”[6]
This is the opposite approach: HIV is permanently locked into a “silent,” latent state so that it can no longer be reactivated. Animal studies have produced promising results, but there is not yet a drug candidate ready for clinical testing in humans.
Therapeutic vaccination
A therapeutic vaccine is intended to train the immune system to control HIV itself. Despite numerous concepts, there is still no convincing proof of principle that they work; this approach is likely to work only in people with a well-preserved immune system.
New approaches are focusing on mRNA technology or powerful immune cells (CD8 cells) that remain intact even after years of treatment.
Siegfried Schwarze:
Setbacks are part of HIV cure research. […] They also provide important insights for the next steps.
CAR-T cells
The body’s own T cells—a type of “sentinel cell” in the immune system—are given an additional receptor in the laboratory that enables them to recognize and destroy HIV-infected cells. This is a principle already successfully used for some types of cancer.
With so-called duoCAR-T cells, two different new receptors are introduced, making it harder for the virus to escape recognition through mutations.
Initial results showed no serious side effects. In some participants, viral control lasted longer after ART was stopped, particularly among those who had started treatment early. However, without preparatory and intensive conditioning, the cells cannot establish themselves in the body with this approach either. The procedure is also complex and expensive.
Broadly neutralizing antibodies (bnAbs)
A small number of people develop antibodies after years without treatment that can not only recognize many HIV variants but also neutralize them. Such antibodies can be produced artificially and administered to patients.
Production is technically challenging and expensive, but administration itself is considerably less burdensome than cell or gene therapy: the antibodies are given as an infusion or injection, and conditioning is not required. Researchers are working on longer-acting versions.
In children in Botswana, three combined antibodies were able to replace daily ART: all ten children maintained an undetectable viral load using the antibodies alone. An important qualification is that the antibodies were administered continuously. Whether the children can control HIV after the antibodies are discontinued remains to be determined in the next phase of the study.
bnAbs are therefore currently among the approaches generating the greatest hopes—but they do not yet constitute a permanent cure.
Setbacks are part of HIV cure research
Failures are a normal part of research across all approaches. For example, several immunomodulatory drugs—substances intended to stimulate the immune system in a targeted way, including N-803/Anktiva and budigalimab/trosunilimab—delayed viral rebound but did not prevent it permanently; their further development was discontinued in 2026.
Such results are not a reason for disappointment. They also provide important insights for the next steps.
Why many HIV cure studies include a treatment interruption
For many people living with HIV, this is probably the most difficult part of a cure study. After all, one of the most important messages in HIV medicine for decades has been that effective HIV treatment should generally never be interrupted without medical supervision.
Why, then, do researchers ask some study participants to do precisely that?
The reason is straightforward: As long as HIV medication completely suppresses the virus, it is difficult to determine whether an experimental treatment actually works. Only when the medication is temporarily paused can researchers determine whether the immune system can control HIV without ART.
This planned interruption is called an Analytical Treatment Interruption (ATI). An ATI is not an ordinary treatment break or an uncontrolled “trial discontinuation.” It takes place exclusively as part of a clinical study under a precisely defined protocol.
The number of HIV copies (viral load), CD4 cell count, and other laboratory values are monitored closely. Before the study begins, the conditions under which HIV treatment will be restarted are established in advance.
Nevertheless, an ATI is not without risks. As the number of HIV copies increases, inflammatory processes may increase as well, and a rising viral load can once again make it possible to transmit HIV to other people. For this reason, counseling, close monitoring, and a plan to protect partners are part of every responsibly conducted study.
Not all HIV cure studies are the same
Public discussion often refers to “the cure study.” In reality, individual studies differ considerably.
Studies involving therapeutic vaccines or broadly neutralizing antibodies are often not very different from other clinical drug trials. The additional risk here primarily involves the usually necessary ATI.
Siegfried Schwarze:
People participate in cure studies for many different reasons. […] None of these motivations is right or wrong, and some people have several reasons.
Other approaches are considerably more complex. These include CAR-T cells and genetically modified stem cells, for example. Conditioning is often necessary—the form of chemotherapy intended to create space for the modified cells. Depending on the procedure, this can result in temporary or long-term side effects.
Even more intensive is an allogeneic stem-cell transplant, meaning the stem cells come from donors who are genetically unrelated to the recipient. Because of its substantial risks, it is considered only for people who also have a life-threatening blood cancer.
What are the reasons for participating in an HIV cure study?
People participate in cure studies for many different reasons. Some hope for a personal medical benefit. Others want to help ensure that future generations may one day be able to live without lifelong HIV treatment. Many also value the intensive medical care provided during a study.
None of these motivations is right or wrong, and some people have several reasons.
It is important, however, to keep expectations realistic. Most current cure studies are still in an early stage of development. Their primary goal is often to assess safety and feasibility—not to prove that a cure has been achieved.
Precisely for this reason, participants make an important contribution. Even studies that do not achieve their original goal provide knowledge that can make future treatments safer and/or more effective.
HIV cure studies: five common misconceptions
“If I participate, I will probably be cured.” Unfortunately, no. Most early studies are primarily designed to investigate the safety and tolerability of new approaches.
“The more burdensome the study, the greater my chance of success.” That is not true either. Greater risk does not automatically mean a greater likelihood of success.
“An ATI means my previous treatment has failed.” Quite the opposite. Precisely because today’s ART is so effective, it often has to be temporarily interrupted so that the effect of a new treatment can actually be assessed.
“If the virus comes back, participating in the study was pointless.” No. Every study contributes to a better understanding of HIV cure research, regardless of whether it achieves the desired outcome.
“I need to decide quickly.” In most cases, there is no need to rush. Unlike many cancers, there is usually enough time to gather information, ask questions, and make the decision carefully.
What study documents do not always explain fully
In the near future, participants will also be sought in Germany for the first HIV cure studies. It is therefore increasingly important to assess the opportunities and risks realistically, because not all risks are described in detail in study documents.
Siegfried Schwarze:
There are good reasons for hope [of an HIV cure] today—but no reason to hastily replace proven HIV treatment with an experimental therapy.
Two points tend to receive relatively little attention:
First, participating in an HIV cure study may prevent someone from taking part in later studies. Someone who participates today may potentially lose the opportunity to participate in a future study that could be larger or more promising.
Second, regulations require participants in studies involving genetic modifications to be followed for more than 15 years. But who will ensure that this follow-up occurs if the company or organization conducting the study no longer exists 15 years from now?
These are not reasons to advise against participation, but they are good reasons to ask specific questions and seek independent advice—for example, from an AIDS service organization or patient advocacy group. The following checklist can help.
HIV cure study checklist: be prepared for the consultation
Before deciding whether to participate in an HIV cure study, it may be helpful to discuss the following questions with the study team:
Study objectives
Is the goal safety, remission (meaning HIV is controlled without medication but may not have disappeared completely), or a permanent cure?
What phase of development is the treatment in?
Benefits and risks
What short- and long-term risks are known?
Is conditioning necessary, meaning a form of chemotherapy?
Is hospitalization required?
What side effects are expected?
What uncertainties remain?
Treatment interruption
Is an ATI planned?
When will ART be restarted?
How frequently will monitoring take place?
How can partners be protected during an ATI?
After the study
How long will follow-up continue?
Who will provide treatment if late side effects occur?
Could participation prevent me from taking part in other studies later?
Personal questions
Does the study fit my current circumstances?
What financial compensation is available?
Am I prepared to accept the time commitment, potential burdens, and uncertainties?
Have I understood all the information and been given enough time to make my decision?
Conclusion
HIV cure research is at an exciting point today. For the first time, several different research approaches are providing indications that long-term control of HIV without medication may be biologically possible. This represents a major scientific advance.
At the same time, almost all of the research is still at an early stage of development. Whether CAR-T cells, gene editing, broadly neutralizing antibodies, or other approaches are involved, all must demonstrate in larger studies that they are not only effective but also safe and practical to use.
For people living with HIV, this means one thing above all: there are good reasons for hope today—but no reason to hastily replace proven HIV treatment with an experimental therapy.
Anyone interested in a cure study should make the decision based neither on fear nor on euphoria, but on good information. Participating is not a decision for or against HIV cure research; it is a decision for or against a specific study with its individual potential benefits and risks.
Further information and sources
Mostly in English; German-language sources at the end.
Background and current overview
Wagner JA, Sandel DA, Deitchman AN et al. (2026): Advances in Immune-Based Approaches for the Cure of HIV Infection. Drugs. doi.org/10.1007/s40265-026-02311-3 — an excellent open-access review of CAR-T cells, bnAbs, ATI, therapeutic vaccines, and current cure strategies.
Zhang C et al. (2026): Searching for a HIV-1 Cure. Theranostics. Freely available online — a comprehensive current review of gene editing, cell therapy, antibodies, and combination therapies.
Stem-cell transplantation and “cured” patients
Vallet L, Lebreton F (2026): L'Actu vue par Remaides: AIDS 2026: Deux nouveaux cas de rémission VIH (July 27, 2026) — an overview of documented cure cases to date.
Allers K, Gaebler C (2026): Not just a viral co-receptor: the role of CCR5 in HIV cure after allogeneic stem cell transplantation. Current Opinion in HIV and AIDS — a current review of the role of CCR5 and why the mutation is not the only factor. (Paywalled.)
Gene editing: CRISPR, Brec1 and EBT-101
Highleyman L (2024): CRISPR gene therapy EBT-101 does not prevent HIV viral rebound.
Beschorner N et al. (2024): Preclinical toxicity analyses of lentiviral vectors expressing the HIV-1 LTR-specific designer-recombinase Brec1. PLOS ONE — preclinical safety data on Brec1 from the developing research group; promising, but not yet confirmed in humans.
CAR-T-cell therapy
Beasley D: Small study shows one-time cell therapy can control HIV infection — an accessible summary of the first duoCAR-T data presented at the 2026 ASGCT conference.
Broadly neutralizing antibodies
Cairns G (2026): African paediatric studies at CROI – HIV remission in children on three bnAbs (March 6, 2026).
International HIV cure research and patient information
IAS – Towards an HIV Cure
NAM aidsmap – overview page, HIV vaccine and cure research. aidsmap is one of the world’s leading and most accessible sources of information for people living with HIV.
In German
Schwarze S. (2025): Vom Labor in die Apotheke – Medikamentenentwicklung und Vermarktung (January 15, 2025) — explains, among other things, the phases of clinical trials.
Fachstelle Gentechnik und Umwelt: Inhärente Risiken von CRISPR/Cas-Anwendungen (PDF), June 2021 — information on the inherent risks of CRISPR/Cas applications.
Editorial notes
[1] Editor’s note: An overview is provided in this French-language article (as of July 2026): L'Actu vue par Remaides: AIDS 2026: Deux nouveaux cas de rémission VIH.
[2] Editor’s note: According to more recent studies, most HIV variants currently transmitted depend on the CCR5 co-receptor to infect cells; estimates are often around 80%. There are also HIV variants that use the other co-receptor, CXCR4.
[3] Editor’s note: The first “Berlin patient” was Timothy Ray Brown.
[4] Editor’s note: See, for example, Lau CY, Adan MA, Maldarelli F (2021): Why the HIV Reservoir Never Runs Dry: Clonal Expansion and the Characteristics of HIV-Infected Cells Challenge Strategies to Cure and Control HIV Infection. Viruses. 13(12):2512.
[5] Editor’s note: See, for example, Tanaka K, Ellis H & Lau J (2025): HIV's Hide and Seek: How Latency Reversal could be a key to curing HIV.
[6] Editor’s note: See, for example, Vansant G, Bruggemans A, Janssens J, Debyser Z (2020): Block-And-Lock Strategies to Cure HIV Infection. Viruses. 12(1):84.
[7] Editor’s note: See, for example, Lee M, Cherrill L, Zacharopoulou P et al. (2026): Time to HIV rebound after infusion of long-acting broadly neutralising antibodies 3BNC117-LS and 10-1074-LS and analytical treatment interruption (the RIO trial). The Lancet HIV. 13, e527–e537.
[8] Editor’s note: See, for example, Simon Collins (2025): CROI 2025: Two bNAbs enable viral suppression off-ART in African women in the FRESH cohort. HIV i-Base.
